Advertising and Promotion Regulatory Affairs Conference

Enforcement activity and use of social media is increasingly shaping how pharmaceutical and medical device companies think about marketing, digital engagement, and third-party relationships. This session examines recent enforcement, marketing trends and regulatory signals that are redefining compliance expectations across pharmaceutical and medical product promotion. Speakers will address how agencies and self-regulatory bodies are approaching emerging areas such as AI-enabled tools, telemedicine, direct-to-patient engagement, and then focus on the growing use of influencers and creators to reach patients, caregivers, and healthcare professionals. Particular attention will be paid to how influencer partnerships introduce unique compliance risks in a highly regulated environment. Panelists will also examine recent actions and guidance from the DOJ, OIG, FDA, the FTC, and the National Advertising Division. This includes how regulators evaluate disclosure practices, company responsibility for influencer statements, and the line between disease awareness and product promotion. The session will conclude with practical takeaways attendees can apply immediately, including insights from BBB National Programs’ new influencer certification initiative.